In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orthopedics Settlement: Puts the Issue to Bed--Or Does It?

Executive Summary

Though government officials and critics in the press painted lucrative consulting arrangements as unscrupulous tools in the hands of Big Ortho, no one's happier to see them go than the orthopedics industry itself. Here’s how the details shake out for the industry, and why executives are actually relieved to have some sticky legal and moral issues disappear. Some even predict that the end result will be lower overhead for their companies.

Related Content

NuVasive: Outpacing a Slowing Spine Market
Biomet Roars Back
Can ConforMIS Recharge Resurfacing with Custom Implants
Navigating Ortho's Choppy Seas: An Interview with Zimmer's David Dvorak
Is Wright Medical Back on Track?
A New Era Dawns in Physician-Device Industry Relationships
In the Wake of the DOJ Settlement, an Orthopedics Industry Split?
Trends for the New Year: Can Medtech Build on the Success of 2007?
Spine Market: Are the Good Times Over?
In the Eye of the Storm


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts